ScoreWhy is Newland Pharmaceutical Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -0.30% and Operating profit at -24.73% over the last 5 years
2
With a fall in Net Sales of -5.84%, the company declared Very Negative results in Mar 26
- The company has declared negative results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Lowest at CNY 69.44 MM
- ROCE(HY) Lowest at 6.32%
- DEBT-EQUITY RATIO (HY) Highest at -41.73 %
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -37.90% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Newland Pharmaceutical Co., Ltd. for you?
Medium Risk, Low Return
Absolute
Risk Adjusted
Volatility
Newland Pharmaceutical Co., Ltd.
-100.0%
-0.37
28.10%
China Shanghai Composite
16.78%
1.20
13.96%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-0.30%
EBIT Growth (5y)
-24.73%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.49
Sales to Capital Employed (avg)
0.45
Tax Ratio
13.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.84%
ROE (avg)
10.96%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
7
Industry P/E
Price to Book Value
0.42
EV to EBIT
0.06
EV to EBITDA
0.04
EV to Capital Employed
0.01
EV to Sales
0.01
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
10.18%
ROE (Latest)
6.18%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-19What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at CNY 69.44 MM
ROCE(HY)
Lowest at 6.32%
DEBT-EQUITY RATIO
(HY)
Highest at -41.73 %
OPERATING PROFIT MARGIN(Q)
Lowest at 17.77 %
RAW MATERIAL COST(Y)
Grown by 15.11% (YoY
PRE-TAX PROFIT(Q)
Fallen at -37.34%
NET PROFIT(Q)
Fallen at -37.92%
Here's what is not working for Newland Pharmaceutical Co., Ltd.
Operating Cash Flow
Lowest at CNY 69.44 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (CNY MM)
Operating Profit Margin
Lowest at 17.77 % and Fallen
In each period in the last five periodsMOJO Watch
Company's profit margin has deteriorated
Operating Profit to Sales
Debt-Equity Ratio
Highest at -41.73 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Pre-Tax Profit
Fallen at -37.34%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (CNY MM)
Net Profit
Fallen at -37.92%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
Raw Material Cost
Grown by 15.11% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
